Meeting
2024 ASCO Genitourinary Cancers Symposium
Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.
Authors
Ryan Michael Antar
George Washington University School of Medicine, Washington, DC
Ryan Michael Antar , Vincent Eric Xu , Olivia French Gordon , Christian Mark Farag , Sarah Azari , Michael Joseph Whalen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 698)
DOI
10.1200/JCO.2024.42.4_suppl.698
Abstract #
698
Poster Bd #
L20
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of care fragmentation in patients receiving neoadjuvant chemotherapy and radical cystectomy for bladder cancer.
First Author: Carlos Riveros
Poster
2021 Genitourinary Cancers Symposium
KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Matt D. Galsky
Poster
2020 Genitourinary Cancers Symposium
Efficacy of neoadjuvant chemotherapy followed by resection in primary and secondary muscle-invasive bladder cancer (MIBC).
First Author: Josiah An
Poster
2019 ASCO Annual Meeting
Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC).
First Author: Benjamin Miron